MARKET

CNSY

CNSY

Cerenome, Inc
NASDAQ
3.150
-0.050
-1.57%
Opening 12:42 08/18 EDT
OPEN
3.200
PREV CLOSE
3.200
HIGH
3.200
LOW
3.090
VOLUME
45.74K
TURNOVER
--
52 WEEK HIGH
23.43
52 WEEK LOW
2.900
MARKET CAP
23.91M
P/E (TTM)
-1.2619
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CNSY last week (0810-0814)?
Weekly Report · 1d ago
Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook
Seeking Alpha · 1d ago
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 4d ago
*Cerenome Affirming Milestone Framework, Outlook Provided When Reporting full-Yr 2026 Fincl Results >CNSY
Dow Jones · 4d ago
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
Barchart · 5d ago
Weekly Report: what happened at CNSY last week (0803-0807)?
Weekly Report · 08/10 09:01
Weekly Report: what happened at PSTV last week (0727-0731)?
Weekly Report · 08/03 09:01
Press Release: Cerenome Launches as an Integrated CNS Oncology Company
Dow Jones · 07/31 12:30
More
About CNSY
Plus Therapeutics, Inc. is a healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, such as CNSide, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, is designed to treat many solid organ cancers, including primary and secondary liver cancers by intra-arterial injections.

Webull offers Plus Therapeutics Inc (USA) stock information, including NASDAQ: CNSY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNSY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNSY stock methods without spending real money on the virtual paper trading platform.